2022 at a Glance Chairman’s Letter CEO’s Report Key Milestones Pipeline Review ESG Financial Reports 39 Kazia Theraputics Limited Annual Report 2022 STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME For the year ended 30 June 2022 Consolidated Note 2022 2021 $ $ Revenue 5 - 15,182,711 Other income 6 24,956 2,192 Finance income 2,094 42,240 Expenses Research and development expense (20,252,152) (14,541,366) General and administrative expense (4,511,463) (7,021,823) Loss on revaluation of contingent consideration 3 (152,287) (2,570,261) Commercialisation expense (127,043) - Loss before income tax benefit (25,015,895) (8,906,307) Income tax benefit 8 368,080 484,347 Loss after income tax benefit for the year attributable to the owners of Kazia Therapeutics Limited (24,647,815) (8,421,960) Other comprehensive income Items that may be reclassified subsequently to profit or loss Net exchange difference on translation of financial statements of foreign controlled entities, net of tax 34,615 1,868 Other comprehensive income for the year, net of tax 34,615 1,868 Total comprehensive income for the year attributable to the owners of Kazia Therapeutics Limited (24,613,200) (8,420,092) Cents Cents Basic earnings per share 32 (18.61) (7.16) Diluted earnings per share 32 (18.61) (7.16) The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes Our Collaborators
RkJQdWJsaXNoZXIy MjE2NDg3